Evommune, Inc.
EVMN
$14.65
$0.584.12%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 27.85% | -28.76% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 45.68% | -19.39% | |||
| Operating Income | -45.68% | 19.39% | |||
| Income Before Tax | -48.78% | 23.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -48.78% | 23.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.78% | 23.34% | |||
| EBIT | -45.68% | 19.39% | |||
| EBITDA | -45.49% | 19.68% | |||
| EPS Basic | -38.64% | 54.98% | |||
| Normalized Basic EPS | -38.63% | 54.97% | |||
| EPS Diluted | -38.64% | 54.98% | |||
| Normalized Diluted EPS | -38.63% | 54.97% | |||
| Average Basic Shares Outstanding | 7.32% | 70.26% | |||
| Average Diluted Shares Outstanding | 7.32% | 70.26% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||